Stay updated on Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the VRP-HER2 vaccine and pembrolizumab breast cancer study is now displayed, including its study plan, participant criteria, outcomes, and record history. The record indicates that the study was terminated and is no longer seeking participants.
    Difference
    52%
    Check dated 2026-11-09T14:58:40.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The study record page now shows a 403 Forbidden message and a Home link. The site revision label also changes from v3.7.2 to v3.8.0.
    Difference
    0.6%
    Check dated 2026-11-02T16:33:52.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    A notice appears above the page announcing NIH website transition updates and explaining that “Super Intelligence” may be used in place of “Artificial Intelligence” in NIH content.
    Difference
    1%
    Check dated 2026-10-26T16:00:24.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-19T21:59:48.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-13T04:47:40.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error page with a basic header and navigation, replacing the normal study record content. This indicates an access issue rather than an update to the study data, with the detailed study sections effectively removed in the current view.
    Difference
    19%
    Check dated 2026-09-21T22:25:13.000Z thumbnail image

Stay in the know with updates to Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Concurrent VRP-HER2 & Pembrolizumab in Breast Cancer Clinical Trial page.